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Cytochrome P450 (CYP) enzymes are heme containing 
monooxygenases. Around 15 of them are responsible for phase I 
metabolism acting mainly to hydroxylate pharmaceuticals and 
exogenous substances, some of which may have the potential to 
be carcinogenic.1 The CYP1 sub-family of enzymes consists of 
1A1, 1B1 and 1A2 isoforms. The CYP1A1 isoform catalyzes 
hydroxylation of a large number of pro-carcinogens, such as 
polyaromatic hydrocarbons (PAHs), oxides, amines, and 
estrogens (E) converting them to cytotoxic, mutagenic and 
carcinogenic chemicals.2-5 Overexpressed CYP1A1 isoform can 
metabolize the PAH benzo[a]pyrene [BaP] into benzo[a]pyrene-
7,8-dihydrodiol-9,10-epoxide which subsequently can form a 
quinone intermediate which can covalently react with DNA and 
lead to DNA damage.6-15 Similarly, CYP1B1 overexpression is 
responsible for the increased metabolism of anticancer drugs 
such as paclitaxel, docetaxel, doxorubicin, mitoxantrone, 
tamoxifen, and cisplatin in various cancer cells.16  As a result, the 
cellular efficacy of cytotoxic drugs is reduced and eventually 
cancer cells, which overexpress CYP1B1, become resistant to a 
variety of chemotherapeutic agents. Recent studies have 
demonstrated that CYP1B1 inhibitors can overcome docetaxel 
resistance,16, 17 as well as cisplatin resistance in CYP1B1-
overexpressing cells.18 
Various biochemical and cellular studies suggest that basal 
expression of CYP1 enzymes in healthy tissue is very low, in 
contrast to tissues exposed to pro-carcinogens or drugs. This 
selective behavior offers an opportunity to a medicinal chemist 
and biologist for prevention of CYP1A1-mediated lung 
carcinogenesis caused by B[a]P in individuals who smoke. 
Several natural and synthetic compounds have been reported 
as potent inhibitors of CYP1 enzymes e.g. resveratrol, quercetin, 
and rosmarinic acid.19-21  In continuation of our efforts in this 
area,
18, 22, 23
 herein we report design and synthesis of 2-pyrrole 
based chalcones, to combat CYP1B1-mediated cisplatin 
resistance and CYP1A1-mediated B[a]P toxicity. A total 23 
chalcones were synthesized as potential CYP1 family inhibitors 
using the classical Claisen-Schimdt condensation.24-26 This 
reaction offers coupling of equimolar amounts of aromatic 
aldehydes and acetophenones in either acidic or basic conditions 
or vice versa. 2-Pyrrole chalcones synthesized using solution 
phase or solid grinding method gives moderate to good yields 
(24-73%). The synthetic scheme is provided in Scheme 1. All 
compounds were characterized by NMR, IR and HRMS analysis.  
All synthesized 2-pyrrole chalcones were screened for 
inhibition of CYP1, CYP2 and CYP3 family enzymes using 
SacchrosomesTM which are endoplasmic reticulum-bound CYP-
reductase complexes isolated from recombinant baker’s yeast, 
Saccharomyces cerevisiae. Results of CYP inhibition are 
depicted in Table 1. In-vitro CYP inhibition data suggest that all 
chalcones selectively inhibit CYP1 enzymes. The 2-pyrrole 
chalcone 3j inhibits all three isoforms of CYP1 with almost equal 
potency. However, another 2-pyrrolyl chalcone derivative 3n 
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selectively inhibits CYP1B1 with an IC50 value of 210 nM. Based 
on in-vitro data, few key structure-activity relationship (SAR) 
features have been drawn for these heterocyclic chalcones. These 
include (a) 2-pyrrole substituted class of CYP1 inhibitors can be 
selective for CYP1B1 isoform (b) halogen or methoxy 
substitution on non-heterocyclic ring (e.g. 2-chloro substituted 
compound 3n) is essential for activity (c) alkoxy substitution on 
the non-heterocyclic ring is critical for potency of CYP1 
inhibition.  
+
O
O
Ar
1 2 3a-w
Ar-CHO NH
a
3a:   Ar = Ph (3-OMe)
3b:   Ar = Ph (2,6-di-OMe)
3c:   Ar = Ph (2-Cl,5-NO2)
3d:   Ar = Ph (2,3-di-OMe)
3e:   Ar = Ph (3,4-Methylene-dioxy)
3f:    Ar = Ph (2,4-di-OMe)
3g:   Ar = Cinnamyl
3h:   Ar = Ph (3,5-di-OMe)
3i:    Ar = Ph (2-F)
3j:    Ar = Ph (2-OMe)
3k:   Ar = Cinnamyl (4-OMe)
3l:    Ar = Ph (4-N(CH3)2)
3m: Ar = Ph (4-OMe)
3n:  Ar = Ph (2-Cl)
3o:  Ar = Ph (3-Br)
3p:  Ar = Ph (3-Br, 4-OMe)
3q:  Ar = Furan-2-yl (5-Et)
3r:   Ar = Ph (3,4.5-tri-MeO)
3s:  Ar = Ph (4-OCF3)
3t:   Ar = Ph (4-COOH)
3u:  Ar = Anthracen-9-yl
3v:  Ar = Ph (3-Cl)
3w: Ar = Ph (4-Br)
HN
 
Scheme 1. Reagents and conditions: (a) 5 equivalents NaOH/KOH 
with solid state grinding using mortar and pestle. 
 
The failure of various CYP inhibitors in drug development is due 
to the lack of drug-like features and cellular efficacy. In order to 
overcome this problem, we established CYP-expressing live 
human cell based assays, for CYP inhibition studies.18, 22, 23 The 
CYP1 inhibitors identified using SacchrosomesTM were tested for 
inhibition of CYP1, CYP2 and CYP3 family of enzymes in live 
human kidney HEK293 cells (results are shown in Table 2).27, 28 
The compound 3s, which was inactive in Sacchrosomes, was also 
tested in live cells, as a negative control. 
Table 2.  The IC50 values for inhibition of CYP s expressed in 
live HEK293 cells by the most potent chalcones identified in 
assays using SacchrosomesTM. 
 
IC50 values for CYP inhibition in live HEK293 cells (µM) 
1A1 1B1 1A2 2D6 2C9 2C19 3A4 
3j 1.2±0.1 1.2±0.1 1.1± 0.1 20±0.6 >10 >10 >10  
3n >20 0.25±0.05 0.9 ± 0.2 >10 >10 >10 >10  
3s >20 >20 >20 >20 >20 >20 >20 
ANF >10 >10 nd nd nd nd nd 
a
α-naphthoflavone (ANF) was used as a control in these studies; The IC50 
values represent mean and standard deviations from three independent 
experiments. nd: not determined 
 
The compounds 3j and 3n bearing methoxy or chloro 
substitutions at 2-position inhibit all three CYP1 family enzymes 
in varying degrees, as it was seen with SacchrosomesTM. It was 
observed that the 2-pyrrole chalcone 3j is not CYP1B1 specific 
since it also inhibits the 1A1 isoform with equal efficacy (IC50 = 
1.2 µM). However, 3n is specific to CYP1B1 inhibitor, IC50 = 
0.25 µM compared to the CYP1A1, IC50 = >20 µM. Nonetheless, 
both 3j and 3n display excellent specificity (>20 fold in 
SacchrosomesTM and live human cells) for CYP1 family enzymes 
with respect to CYP2 and CYP3 family isoforms. Inhibition of 
CYP2/ CYP3 enzymes can be the cause of deleterious drug-drug 
interactions which often thwart further drug development. 
SacchrosomesTM and recombinant live human cell assays indicate 
that the 2-pyrrole chalcones 3j and 3n can avoid such harmful 
interactions.  
In order to gain further insight into the experimental CYP 
inhibition efficacy and selectivity, molecular modeling studies 
 
Table 1. CYP inhibition activity of pyrrole chalcones 3a-w in SacchrosomesTM  
Entry IC50 values for CYP inhibition (µM) 
1A1 1B1 1A2 2D6 2C9 2C19 3A4 
3a 6.2±0.2 5.2± 0.1 1.5±0.1 11±0.2 >20 >20 >20  
3b 10.8 ±0.3 >20 10.0±0.5 18±0.4 >20 >20 >20  
3c >20 >20 10.9±0.4 12± 0.2 >20 >20 >20  
3d 5.2±0.2 >20 9.2±0.4 16± 0.3 >20 >20 >20  
3e 5.8±0.2 >20 9.7±0.5 14± 0.2 >20 >20 >20  
3f 11.8±0.2 >20 10.0±02 11± 0.1 >20 >20 >20  
3g >20 >20 10.5±0.3 12±0.2 >20 >20 >20  
3h 6.1±0.4 >20 9.0±0.2 15±0.4 >20 >20 >20  
3i >20 2.7±0.1 2.2±0.08 16±0.4 >20 >20 >20  
3j 0.9±0.07 0.9 ± 0.1 1.1±0.04 20±0.6 >20 >20 >20  
3k >20 >20 13±0.2 18 ±0.4 >20 >20 >20  
3l >20 >20 12.5±0.1 13±0.2 >20 >20 >20  
3m >20 >20 11.8±0.2 16±0.3 >20 >20 >20  
3n 9.1±0.4 0.2±0.04 0.7±0.1 12±0.16 >20 >20 >20  
3o >20 13±0.4 >20 14±0.25 >20 >20 >20  
3p >20 >20 17±0.5 13±0.3 >20 >20 >20  
3q >20 9.2±0.2 2.5±0.08 17±0.4 >20 >20 >20  
3r >20 >20 15±0.4 14±0.2 >20 >20 >20  
3s >20 >20 >20 16±0.3 >20 >20 >20  
3t >20 >20 >20 18±0.4 >20 >20 >20  
3u >20 >20 >20 12±0.15 >20 >20 >20  
3v 16±0.5 1.5±0.1 12±0.3 14 ±0.2 >20 >20 >20  
3w >20 8.5±0.2 13.2±0.2 18±0.4 >20 >20 >20  
ANF 0.01± 0.002 0.05± 0.01 0.03± 0.01 >20 >20 >20 >20 
a
α-naphthoflavone (ANF) was used as a control in these studies; The IC50 values represent mean and standard deviations from three 
independent experiments.  
 
 
  
were performed with the chalcones using the 3D structures of 
isoforms of the CYP1, CYP2 and CYP3 sub-families. Analysis 
of ANF-bound CYP1A1 and CYP1B1 X-ray derived structures 
indicate that they share similar characteristics such as canonical 
helices, β-sheets, and two short helixes F’ and G’, which overall 
form the binding site for ANF. The ligand ANF interacts with the 
macromolecules by hydrophobic pi-pi interactions which involve 
multiple aromatic residues of CYP1A1 and CYP1B1.29-31  
Upon analysis of molecular models, it was observed that the 
heteroaromatic nucleus of 3j interacts with the CYP1A1 heme-
porphyrin complex and the 2-methoxyphenyl ring interacts with 
the Phe-224 residue by pi-pi interactions. In case of CYP1B1, the 
pyrrole ring of 3j interacts with the heme unit and the 2-methoxy 
phenyl ring interacts with the Phe-231 residue (which 
corresponds to Phe-224 of CYP1A1). Similarly, the most potent 
2-chloro substituted analog, 3n, interacts with CYP1B1’s Phe-
231 residue in its F-helix by pi-pi interactions. However, the ANF 
binding site of CYP1B1 contains the less hydrophobic Gln-332, 
corresponding to the highly hydrophobic Phe-319 residue of 
CYP1A1.This allows moderate flexibility in the substrate binding 
site, leading to a 180° flip in ligand orientation which is also seen 
in the ANF-CYP1B1 X-ray crystal structure.30, 31 The 180° flip in 
orientation is stabilized by H-bonding with the Gln332-Asp333 loop 
in I helix. Overall, these interactions prevent formation of a 
reactive heme-oxo intermediate between substrate, heme 
complex and the CYP1 enzyme necessary for the oxidative 
metabolism of a specific substrate, e.g. B[a]P, estrogen or 
anticancer drugs. This is shown in Figure 1. For selectivity 
studies, the ligand-bound 10 Å binding site of CYP2D6 and 
CYP3A4 isoforms were aligned to CYP1A1’s binding site.  
CYP2 and CYP3 family enzymes have large substrate binding 
cavity which is flexible enough to accommodate structurally 
diverse chemical scaffolds. Due to this, 3j and 3n interactions 
with heme complex become distorted and thus both compounds 
lose their inhibitory activity for these isoforms (images are 
shown in supporting information - Section S3).  
The aromatic hydrocarbon receptor, AhR, a member of the 
hormone receptor family, is a transcription factor responsible for 
induction of the CYP1 sub-family of genes. PAHs like B[a]P act 
as AhR ligands. Ligand-bound AhR induces transcription of 
CYP1 genes. It is reported that certain compound families that 
function as CYP1 enzyme inhibitors can compete with PAHs for 
the ligand-binding site of AhR21, 32 to act as antagonists for 
repression of CYP1 gene expression. In order to study the role of 
the 2-pyrrole chalcones in AhR signaling, a yeast cell system was 
used to assess the regulation of a reporter, the enhanced green 
fluorescence protein (eGFP) which is controlled by a basal 
promoter containing a concatamer of five xenobiotic response 
element (XREs). A tripartite complex consisting of AhR, its co-
activator ARNT and a PAH ligand (e.g. B[a]P) binds to the XRE 
concatamer to induce eGFP expression. The optimization of 
B[a]P concentration, used for induction, is provided in Table S3. 
In yeast, the 2-pyrrole chalcones, 3j and 3n, act as concentration-
dependent antagonists of AhR, activated by B[a]P (as shown in 
Table 3), with IC50 values of 1.5 µM and 7.6 µM, respectively. 
The compound 3s, which was inactive in Sacchrosomes and live 
cells, was also tested in this assay, as a negative control.  
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Figure 1.  Interactions of 3j with 1A1 and 1B1 (A and B) and 3n with 1A1 and 1B1 (C and D) enzyme isoforms. 
  
Table 3. Concentration-dependent antagonism of AhR, relative  
to its activation by B[a]P at 0.75 µM, by the most potent 
CYP1A1 and CYP1B1 inhibitors, identified in Sacchrosomes and 
recombinant CYP-expressing human cells. 
 AhR-ARNT complex in eGFP units at  
Entry  1 µM 5 µM 10 µM 20 µM 
- 955  ± 9 955  ± 9 955  ± 9 955  ± 9 
3j 600  ± 9 220  ± 5 150  ± 9 120  ± 1.2 
3n 920  ± 9 770  ± 7 455  ± 5 285  ± 5 
3s 955  ± 9 955  ± 9 955  ± 9 955  ± 9 
All values, presented in eGFP units (excitation/emission monitored at 
489/509 nm), represent the mean and standard deviations of three 
independent experiments.  
 
CYP family of enzymes is part of a metabolic machinery of 
the cell.4, 16, 33 Recent studies have shown a correlation between 
CYP1B1 expression in human cells and the metabolism of 
anticancer drugs such as paclitaxel, docetaxel, doxorubicin, 
mitoxantrone, tamoxifen and cisplatin.16 CYP1B1-mediated 
metabolism leads to decrease in the cellular efficacy of cytotoxic 
drugs, and eventually cancer cells become resistant to these 
drugs. Such issues of drug metabolism were specifically been 
addressed by using CYP1B1-specific inhibitors.16, 18 Cui et al. 
and Horley et al. have shown improvement in docetaxel and 
cisplatin efficacy by potent CYP1B1 inhibitors.16, 18 Therefore, 
CYP1B1 inhibitors confirmed in live human cells were tested for 
reduction in resistance to cisplatin in adherent HEK293 cells. The 
introduction of CYP1B1 gene bearing plasmid in HEK293 
reduces the cytotoxicity of cisplatin by increasing the EC50 from 
10.5 to 65 µM (shown in Table S4 of supporting information). 
CYP1B1 inhibitors 3j and 3n completely restore cytotoxicity of 
cisplatin at the tested concentrations, as shown in Figure 2. Due 
to inhibition of cisplatin metabolism, the EC50 of cisplatin was 
restored to ~10 µM. This demonstrates that CYP1B1 inhibitors 
have the ability to re-establish cisplatin’s cytotoxicity in cells 
harboring the CYP1B1 gene. The compound 3s, which was 
inactive in live cells assays, does not reverse the cisplatin-
resistance. 
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Figure 2. Overcoming cisplatin resistance by CYP1B1 inhibitors. A range of 
concentrations of cisplatin (0.05 µM – 100 µM) were used, in the presence of 
6 x IC50 values of compounds 3j and 3n, whereas compound 3s and ANF (α-
naphthoflavone) were used at 20µM concentrations. IC50 values had been 
determined in the human cell assay where cells were grown in suspension. 
HEK293 cells were transfected with pcDNA3.1/hCYP1B1 (the plasmid 
encoding the human CYP1B1 gene). All values, presented in µM 
concentrations, represent the mean and standard deviations of three 
independent experiments. 
 
B[a]P is a pro-carcinogen, which upon metabolism by 
CYP1A1 enzyme is converted into benzo[a]pyrene-6,7-
dihydrodiol-9, 10 epoxide which is then able to intercalate DNA, 
thus producing toxicity. In the literature various CYP1A1 
inhibitors have been reported to protect cells from B[a]P 
toxicity.20, 32  The B[a]P EC50 values in untransfected cells and 
cells transfected with the CYP1A1 gene-bearing plasmid are 
around 14 and 0.8 µM, respectively (shown in Table S5 of 
Supporting Information), indicating toxicity of B[a]P is mediated 
by expression of the CYP1A1 gene. The CYP1A1 inhibitor 3j 
was tested for chemo-preventive activity that would avert 
CYP1A1 mediated B[a]P toxicity in HEK293 cells. It was 
observed that 3j rescued cells from B[a]P toxicity, which is 
shown in Figure 3.  Compounds 3s and 3n which were inactive 
against CYP1A1, does not rescue cells from B[a]P toxicity. 
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Figure 3. Protection from CYP1A1 mediated B[a]P toxicity by CYP1A1 
inhibitors. A range of concentrations of B[a]P (0.05 µM – 100 µM) were 
used, in the presence of 8 x IC50 value of 3j, whereas compounds 3n, 3s and 
ANF (α-naphthoflavone) were used at 20 µM concentrations. IC50 values 
were determined in the human cell assay where cells were grown in 
suspension. HEK293 cells were transfected with pcDNA3.1/hCYP1A1 (the 
plasmid which encodes the human CYP1A1 gene). All values, presented in 
µM concentrations, represent the mean and standard deviations of three 
independent experiments. 
In summary, CYP1B1 structure-guided information, allowed 
us to develop SAR for 2-pyrrolyl chalcones as CYP1 family 
inhibitors. CYP1B1 selectivity can find potential for reversal of 
cisplatin resistance through restoration of cisplatin’s toxicity in 
human cancer cells, while CYP1A1 inhibitory activity can find 
application in the prevention of cancer. Further studies, based on 
these findings, could lead to the discovery of novel modulators 
that would allow chemo-prevention and overcome chemo-
resistance in cancer. 
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